CTSO
Cytosorbents Crp
5.30$
-3.4%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 67.9% | 54.6% | 48.2% | 41.2% | 37.0% | 32.3% | 28.0% | 27.5% | 40.2% | 29.4% | 30.1% | 28.5% | |
| 32.1% | 45.4% | 51.8% | 58.8% | 63.0% | 67.7% | 72.0% | 72.5% | 59.8% | 70.6% | 69.9% | 71.5% | |
| 77.3% | 95.4% | 58.3% | 30.3% | 38.1% | 53.1% | 22.3% | 40.8% | 43.6% | 50.2% | 21.4% | 13.7% | |
| 217.4% | 197.5% | 149.7% | 115.3% | 113.0% | 107.5% | 79.9% | 95.9% | 6.4% | 121.8% | 98.3% | 96.2% | |
| 263.6% | 274.8% | 191.9% | 132.3% | 140.0% | 151.0% | 98.3% | 129.2% | 150.6% | 173.4% | 116.1% | 109.9% | |
| -231.4% | -229.4% | -140.0% | -73.6% | -77.0% | -83.3% | -26.3% | -56.7% | -90.9% | -102.8% | -46.2% | -38.4% | |
| 9.9% | 0.2% | 2.8% | 5.6% | 7.2% | 4.5% | 3.0% | 10.0% | 0.4% | 0.5% | 3.9% | 7.0% | |
| -308.6% | -208.5% | -149.4% | -68.3% | -88.0% | -89.4% | -22.7% | -63.1% | -97.7% | -96.7% | -63.0% | -23.2% | |
| -12.3% | -8.0% | -3.9% | -5.1% | -3.1% | -4.8% | -2.9% | -1.8% | -3.1% | -2.6% | -4.8% | -1.1% | |
| -296.4% | -200.5% | -145.5% | -63.2% | -85.0% | -84.6% | -19.9% | -61.2% | -94.6% | -94.1% | -58.2% | -22.1% | |
| -229.4% | -226.6% | -144.6% | -61.1% | -78.9% | -80.8% | -24.6% | -60.2% | -86.5% | -89.7% | -54.1% | -11.8% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.